Anti-viral COVID-19 treatment now available in the Netherlands for 1,250 Euros

1 December 2022 - The anti-viral medication approved to treat COVID-19 is now available on the Dutch market, the Dutch Association ...

Read more →

Anti-viral drug should not be first choice in treating COVID-19

3 December 2022 - The most widely prescribed anti-viral drug in Australia, molnupiravir, should no longer be routinely given for ...

Read more →

COVID-19 vaccine safety report (1 December 2022)

1 December 2022 - To 27 November 2022, the TGA has received 709 reports which have been assessed as likely to ...

Read more →

Joint statement: NICE and SMC/HIS collaboration

25 November 2022 - NICE and SMC/HIS collaboration on the health technology appraisal of tixagevimab–cilgavimab (Evusheld) for preventing COVID-19. ...

Read more →

Outcome in relation to discussion of COVID-19 oral treatments – November 2022 PBAC meeting

24 November 2022 - A PBAC outcome in relation to discussion of COVID-19 oral treatments at the November 2022 meeting has ...

Read more →

TLV subsidises anti-viral treatment of COVID-19 to risk groups

21 November 2022 - Paxlovid, which treats patients who are at risk of becoming seriously ill from COVID-19, will be ...

Read more →

Moderna applies to Swissmedic for authorisation of a second bivalent COVID-19 vaccine

18 November 2022 - Application submitted for Spikevax Bivalent Original / Omicron BA.4-5 (mRNA-1273.222) ...

Read more →

COVID-19 vaccine safety report (17 November 2022)

17 November 2022 - To 13 November 2022, the TGA has received 706 reports which have been assessed as likely to ...

Read more →

Novavax’s COVID-19 booster has been approved for adults, Health Canada says

17 November 2022 - Health Canada said Thursday it has approved the booster dose of Novavax‘s Nuvaxovid COVID-19 vaccine for ...

Read more →

NICE recommends 3 treatments for COVID-19 in draft guidance

16 November 2022 - Three treatments for COVID have been recommended in draft NICE guidance released today for public consultation. ...

Read more →

New COVID-19 vaccines for eligible Australians

15 November 2022 - The Australian Government has accepted a recommendation from the Australian Technical Advisory Group on Immunisation (ATAGI) on ...

Read more →

TGA grants provisional determination to Pfizer’s COVID-19 bivalent (Comirnaty Bivalent Omicron BA.4/BA.5) booster dose vaccine

16 November 2022 - On 15 November 2022, the TGA granted a provisional determination to Pfizer’s bivalent COVID-19 vaccine candidate: tozinameran ...

Read more →

ATAGI recommendations on use of the Pfizer COVID-19 vaccine for children aged 6 months to 4 years

15 November 2022 - On 29 September 2022, the TGA provisionally approved Comirnaty (Pfizer) COVID-19 vaccine for use in children ...

Read more →

ATAGI recommendations on use of the Pfizer bivalent (Original/Omicron BA.1) COVID-19 vaccine

15 November 2022 - On 27 October 2022, the TGA provisionally approved the Pfizer (Comirnaty) Bivalent Original/Omicron BA.1 vaccine (subsequently referred ...

Read more →

ATAGI update on boosters following COVID-19 meeting on 11 November 2022

15 November 2022 - An update from the Australian Technical Advisory Group on Immunisation (ATAGI) following their meeting on 11 November ...

Read more →